News and press releases about the Joshua Frase Foundation and its efforts behind CNM/MTM

Page 1 of 3  > >>

Fri, Sep 17, 2021

The biggest questions facing gene therapy, the XLMTM community, and Astellas after fourth patient death

After three patients died last year in an Astellas gene therapy trial, the company halted the study and began figuring out how to safely get the program back on track. They...
Read More

Tue, Sep 14, 2021

Fourth boy dies in Astellas-Audentes gene therapy trial, raisingfresh fears for the field

A fourth boy has died in the Astellas-Audentes gene therapy trial for a rare muscle-wasting disease, thecompany announced Tuesday morning.
Read More

Thu, Jul 16, 2020

A Tale of Two Clinical Trials: Gene Therapy for a Rare Disease and a Vaccine for COVID-19

Encouraging preliminary findings in a phase I clinical trial for a COVID-19 vaccine were widely reported as soon as the paper appeared in The New England Journal of...
Read More

Tue, Jul 07, 2020

Gene Therapy: It’s Time to Talk about High-Dose AAV

A week before the 2020 virtual American Society for Gene & Cell Therapy conference, a tragedy took place in the rare disease and gene therapy communities. On May 6, the...
Read More

Sat, Jun 27, 2020

Two patients die in now-halted study of Audentes gene therapy

Two children with a rare neuromuscular disease have died after receiving a high dose of a gene therapy in a clinical trial run by Audentes Therapeutics, according to two...
Read More

Thu, Jun 11, 2020

Amid COVID 19 Crisis, Joshua Frase Foundation Leads Search Spanning Two Continents to Deliver Ventilator to Ailing Child in Ecuador

One-Year-Old With Rare Centronuclear Myopathy Diagnosis Gets Life Saving Ventilator Thanks To Dauntless Network of Families in U.S. and Europe.
Read More

Wed, Sep 18, 2019

The importance of patient registries. Recently, the Joshua Frase Foundation's patient registry was used in collaboration in this published paper, RECENSUS.

Mortality and respiratory support in X-linked myotubular myopathy: a RECENSUS retrospective analysis
Read More

Tue, May 07, 2019

How this promising gene therapy for a rare neuromuscular disease was fueled by passionate parents and a dog

Many treatments for rare diseases begin with families who work tirelessly, sometimes for decades, to fund the initial studies leading to the clinic. For X-linked Read More

Wed, May 01, 2019

Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy

New data include 48 weeks of follow-up for six treated patients in dose Cohort 1 and 24 weeks for three treated patients in dose Cohort 2 ...
Read More

Tue, Apr 30, 2019

Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’

Company expects to initiate Phase 1 / 2 study 'Unite-CNM' in 2H2019 Strasbourg (France), April 30, 2019 Dynacure, a...
Read More

Mon, Jul 09, 2018

The Matriarch of the First MTM Dog Colony...The Power of Patient Advocacy

The Joshua Frase Foundation (JFF) is a non-profit organization founded with a simple yet seemingly unattainable vision: to find a cure for Myotubular Myopathy (MTM). The...
Read More

Thu, Jun 21, 2018

Rare Leader: Alison Rockett Frase, President of the Joshua Frase Foundation

The Basics Name : Alison Rockett Frase Title : President, co-founder, and patient advocate ...
Read More

Thu, Jun 07, 2018

Gene Therapy for Myotubular Myopathy: Early Signs of Success!

Parents cherish developmental milestones, from a newborn’s grip of an offered finger; to an infant’s holding her head up the first time; to rolling over, creeping, and...
Read More

Fri, Jun 01, 2018

From Canines to a Cure

Read More

Wed, Feb 28, 2018

A Boy With the Will to Live: Biobanking Contributing to Breakthroughs in Rare Diseases

Joshua Frase was born on February 2, 1995. When Joshua was three months old, a muscle biopsy revealed that he had the ultra-rare X-linked myotubular myopathy (XLMTM), a...
Read More

Wed, Nov 22, 2017

UW, Family Rewriting Neuromuscular Research

Physicians and researchers at the UW Medicine Institute for Stem Cell and Regenerative Medicine have partnered up with a nonprofit foundation in one of the leading efforts to...
Read More

Tue, Oct 17, 2017

Transnetyx produces "Brick in the Wall," second short film in its Love Letter Series

MEMPHIS, Tenn., Oct. 17, 2017 /PRNewswire/ -- Transnetyx, an automated genotyping company that serves biomedical researchers worldwide, today announced the premier of the...
Read More

Wed, Oct 11, 2017

The Joshua Frase Foundation for Congenital Myopathy Research, Inc.

Article on Alison's speech at the National Animal Interest Alliance, October 2017
Read More

Thu, May 18, 2017

KIRO 7 Investigates Revolutionary Treatment in Dogs to be Tested in Children

Our recent campaign to increase participation in our Family Registry was published in MDA Quest Magazine, and can be seen below.

get pinned